TRAM-34

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

TRAM-34

CAS No. : 289905-88-0

MCE 国际站：TRAM-34

产品活性：TRAM-34 是一种选择性的钙激活 K⁺ 通道 (IKCa1)阻断剂，K_d 为 20 nM。

研究领域：Membrane Transporter/Ion Channel

作用靶点：Potassium Channel

In Vitro: TRAM-34 selectively blocks the IKCa1 current (K_d=25 nM), TRAM-34 also blocks IKCa1 currents in human T84 colonic epithelial cells with equivalent potency (K_d=22 nM). TRAM-34 inhibits the cloned and the native IKCa1 channel in human T lymphocytes with a K_d of 20-25 nM and is 200- to 1,500-fold selective over other ion channels. The dose-response curve reveals a K_d of 20±3 nM and a Hill coefficient of 1.2 with 1 μM calcium in the pipette.
TRAM-34, a specific inhibitor of K_Ca 3.1 channels increased or decreased cell proliferation depending on the concentration. At intermediate concentrations (3-10 μM) TRAM-34 increased cell proliferation, whereas at higher concentrations (20-100 μM) TRAM-34 decreased cell proliferation. The enhancement of cell proliferation caused by TRAM-34 is blocked by the oestrogen receptor antagonists ICI182,780 and Tamoxifen. TRAM-34 also increases progesterone receptor mRNA expression, decreased oestrogen receptor-α mRNA expression and reduced the binding of radiolabelled oestrogen to MCF-7 oestrogen receptor, in each case mimicking the effects of 17β-oestradiol.

In Vivo: Mice (n=5) injected intravenously with a single dose of TRAM-34 (0.5 mg/kg; 29 μM) appeared clinically normal during the 7-day study. The body-weight data of the TRAM-34-treated group (day 1:17.8 g; day 7: 27.0 g) are similar to control mice injected with the vehicle (day 1: 17.4 g; day 7: 23.4 g). Collectively, data from these limited toxicity studies suggest that TRAM-34 is not acutely toxic at ≈500-1,000 times the channel-blocking dose.
Treatment with TRAM-34 results in a significant reduction in hematoxylin & eosin (H&E) defined lesion area with the mean infarct size being reduced from 22.6±3.6% in the controls (n=8) to 11.3±2.8% in rats treated with 10 mg/kg TRAM-34 (n=6, mean±s.e.m., P=0.039) and to 8.1±1.9% in rats treated with 40 mg/kg TRAM-34 (n=8; P=0.004). The treatment also tended to reduce brain shrinkage. However, the results are only statistically significant with 40 mg/kg TRAM-34 (P=0.013), but not for the 10 mg/kg group (P=0.11).

相关产品：Bioactive Compound Library Plus  |  Membrane Transporter/Ion Channel Compound Library  |  Anti-Alzheimer's Disease Compound Library  |  Neurodegenerative Disease-related Compound Library  |  Potassium Channel Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Highly Selective Inhibitors Library  |  Ion Channel Compound Library  |  Nigericin sodium salt  |  Yoda 1  |  BAPTA-AM  |  Minocycline hydrochloride  |  Branaplam  |  Rosuvastatin Calcium  |  SCH-23390 hydrochloride  |  Glibenclamide  |  Quinidine (15% dihydroquinidine)  |  Tetrandrine  |  Carbamazepine  |  20(S)-Ginsenoside Rg3  |  DCPIB  |  E-4031  |  Amiodarone hydrochloride  |  Minoxidil  |  Tannic acid  |  (±)-Naringenin  |  Quinine  |  Terfenadine  |  SKF-96365 hydrochloride  |  Mefloquine hydrochloride  |  4-Aminopyridine  |  GW9508  |  PAP-1  |  Astemizole  |  Flufenamic acid  |  Guanosine 5'-diphosphate disodium salt  |  Tolbutamide  |  Atpenin A5

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds